Viracta Therapeutics, Inc.
Biotechnology ResearchCalifornia, United States11-50 Employees
Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.
Insights
Growing Clinical Pipeline Viracta is actively advancing its clinical development program with ongoing Phase 1b/2 studies for Nana-val in EBV+ lymphomas and nasopharyngeal cancers, presenting opportunities for partnerships or customized clinical solutions.
Focused Oncology Expertise As a precision oncology firm targeting virus-associated malignancies, Viracta's specialization allows for tailored collaborations in biotech R&D, diagnostic development, and targeted therapy distribution.
Financial Resources With a funding pool of $50 million and recent revenue generation between $1M and $10M, the company has growth potential that could lead to expansion needs in clinical infrastructure, technology, and commercialization support.
Leadership Changes Strategic hires such as Chief Medical Officer Darrel P. Cohen and CFO Michael Faerm reflect a focus on strengthening leadership capabilities, indicating potential demand for consulting, advisory, or operational solutions.
Innovation and Publishing Viracta's recent publication in Blood Advances highlights its commitment to innovative research, offering prospects for collaborative research tools, data management solutions, and advanced analytics partnerships.
Viracta Therapeutics, Inc. Tech Stack
Viracta Therapeutics, Inc. uses 8 technology products and services including Matomo, Google Cloud CDN, BootstrapCDN, and more. Explore Viracta Therapeutics, Inc.'s tech stack below.
- MatomoAnalytics
- Google Cloud CDNContent Delivery Network
- BootstrapCDNContent Delivery Network
- Google Fonts APIFont Scripts
- Backbone.jsJavascript Frameworks
- FlywheelPlatform As A Service
- Twenty FourteenWeb Platform Extensions
- NginxWeb Servers
Media & News
Viracta Therapeutics, Inc.'s Email Address Formats
Viracta Therapeutics, Inc. uses at least 1 format(s):
| Viracta Therapeutics, Inc. Email Formats | Percentage |
| FLast@viracta.com | 96% |
| Last@viracta.com | 3% |
| LFirst@viracta.com | 1% |
Frequently Asked Questions
Where is Viracta Therapeutics, Inc.'s headquarters located?
Viracta Therapeutics, Inc.'s main headquarters is located at 2533 South Coast Highway 101 Cardiff by The Sea, California 92007 United States. The company has employees across 1 continents, including North America. What is Viracta Therapeutics, Inc.'s phone number?
You can contact Viracta Therapeutics, Inc.'s main corporate office by phone at +1-858-400-****
What is Viracta Therapeutics, Inc.'s stock symbol?
Viracta Therapeutics, Inc. is a publicly traded company; the company's stock symbol is VIRX. What is Viracta Therapeutics, Inc.'s official website and social media links?
Viracta Therapeutics, Inc.'s official website is viracta.com and has social profiles on LinkedIn.What is Viracta Therapeutics, Inc.'s SIC code NAICS code?
Viracta Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).How many employees does Viracta Therapeutics, Inc. have currently?
As of February 2026, Viracta Therapeutics, Inc. has approximately 29 employees across 1 continents, including North America. Key team members include Cfo: G. A.Chief Marketing Officer: W. M.President And Ceo: M. R.. Explore Viracta Therapeutics, Inc.'s employee directory with LeadIQ.What industry does Viracta Therapeutics, Inc. belong to?
Viracta Therapeutics, Inc. operates in the Biotechnology Research industry. What technology does Viracta Therapeutics, Inc. use?
Viracta Therapeutics, Inc.'s tech stack includes MatomoGoogle Cloud CDNBootstrapCDNGoogle Fonts APIBackbone.jsFlywheelTwenty FourteenNginx. What is Viracta Therapeutics, Inc.'s email format?
Viracta Therapeutics, Inc.'s email format typically follows the pattern of FLast@viracta.com. Find more Viracta Therapeutics, Inc. email formats with LeadIQ. How much funding has Viracta Therapeutics, Inc. raised to date?
As of February 2026, Viracta Therapeutics, Inc. has raised $50M in funding. The last funding round occurred on Nov 05, 2021 for $50M.
Company Overview
- Headquarters
- 2533 South Coast Highway 101 Cardiff by The Sea, California 92007 United States
- Phone number
- +1-858-400-****
- Website
- viracta.com
- SIC Code
- 8733 - Noncommercial Research Organizations
- Stock Symbol
- VIRX
- NAICS Code
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Employees
- 11-50
Media & News
Funding & Financials
- $50M
Viracta Therapeutics, Inc. has raised a total of $50M of funding over 10 rounds. Their latest funding round was raised on Nov 05, 2021 in the amount of $50M.
- $1M$10M
Viracta Therapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M
Funding & Financials
- $50M
Viracta Therapeutics, Inc. has raised a total of $50M of funding over 10 rounds. Their latest funding round was raised on Nov 05, 2021 in the amount of $50M.
- $1M$10M
Viracta Therapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M
Company Leadership
G. A.Cfo
W. M.Chief Marketing Officer- M. R.President And Ceo
- J. D.Senior Director Of Clinical Operations
- M. D. F.Senior Director Medical Writing
Employee Directory
- P. D.Principal
- S. R.Independent Member, Board Of Directors
P. D.Research Associate- R. C.Associate Director (contract), Regulatory Operations
1-888-653-2347 
support@leadiq.com © LeadIQ, Inc. All rights reserved.
